Cordycepin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cordycepin
Accession Number
DB12156
Type
Small Molecule
Groups
Investigational
Description

Cordycepin has been used in trials studying the treatment of Leukemia.

Structure
Thumb
Synonyms
Not Available
External IDs
NSC-401022 / NSC-63984
Categories
UNII
GZ8VF4M2J8
CAS number
73-03-0
Weight
Average: 251.2419
Monoisotopic: 251.101839307
Chemical Formula
C10H13N5O3
InChI Key
OFEZSBMBBKLLBJ-BAJZRUMYSA-N
InChI
InChI=1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,10+/m0/s1
IUPAC Name
(2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
SMILES
[H][[email protected]@]1(CO)C[[email protected]@]([H])(O)[[email protected]@]([H])(O1)N1C=NC2=C(N)N=CN=C12

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cordycepin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Cordycepin.Experimental
AmlodipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cordycepin.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Cordycepin is combined with Amrinone.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Cordycepin is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Barnidipine.Approved
BencyclaneThe risk or severity of adverse effects can be increased when Cordycepin is combined with Bencyclane.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Benidipine.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Cordycepin.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Cordycepin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Cordycepin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cordycepin.Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Cordycepin is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Caroverine.Experimental
CilnidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cordycepin.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Clevidipine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Cordycepin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cordycepin.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Cordycepin.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Cordycepin.Experimental
DarodipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Darodipine.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cordycepin.Approved
DidanosineDidanosine can cause a decrease in the absorption of Cordycepin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cordycepin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Cordycepin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cordycepin.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Cordycepin is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Cordycepin.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Cordycepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Dotarizine.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Efonidipine.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Cordycepin is combined with Eperisone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Cordycepin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Fendiline.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Flunarizine.Approved
FosphenytoinThe serum concentration of Cordycepin can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Gallopamil.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Cordycepin.Experimental
IsradipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Isradipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lamotrigine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Cordycepin.Experimental
LercanidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lercanidipine.Approved, Investigational
LidoflazineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lidoflazine.Experimental
LosartanThe metabolism of Losartan can be decreased when combined with Cordycepin.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cordycepin is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Manidipine.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Cordycepin.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Mibefradil.Investigational, Withdrawn
NaftopidilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Naftopidil.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nitrendipine.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Cordycepin.Experimental, Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Cordycepin is combined with Otilonium.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Cordycepin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cordycepin.Approved, Vet Approved
PerhexilineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Perhexiline.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Cordycepin.Experimental
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cordycepin.Approved, Vet Approved
PimozideCordycepin may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Cordycepin is combined with Pinaverium.Approved
PregabalinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cordycepin.Approved, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Cordycepin.Experimental
QuinidineThe metabolism of Quinidine can be decreased when combined with Cordycepin.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Cordycepin.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Cordycepin.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Cordycepin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Cordycepin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cordycepin.Approved, Investigational
RisedronateThe risk or severity of adverse effects can be increased when Cordycepin is combined with Risedronate.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Cordycepin.Approved
SucralfateSucralfate can cause a decrease in the absorption of Cordycepin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Cordycepin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Cordycepin.Approved, Investigational
TerodilineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Terodiline.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Cordycepin is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Cordycepin is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cordycepin.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Vinpocetine.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Cordycepin is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Cordycepin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C08431
PubChem Compound
6303
PubChem Substance
347828450
ChemSpider
6064
BindingDB
50144950
ChEBI
29014
ChEMBL
CHEMBL305686
HET
3AD
PDB Entries
1fa0 / 3b4b / 3b4c / 3onf / 5m5k

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP-0.85ALOGPS
logP-1.4ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)4.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area119.31 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity62.1 m3·mol-1ChemAxon
Polarizability24.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as purine 3'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 3.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Purine 3'-deoxyribonucleosides
Direct Parent
Purine 3'-deoxyribonucleosides
Alternative Parents
6-aminopurines / Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds / Primary amines
show 3 more
Substituents
Purine 3'-deoxyribonucleoside / 6-aminopurine / Imidazopyrimidine / Purine / Aminopyrimidine / N-substituted imidazole / Pyrimidine / Imidolactam / Azole / Imidazole
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
adenosines, 3'-deoxyribonucleoside (CHEBI:29014)

Drug created on October 20, 2016 15:29 / Updated on November 09, 2017 05:03